NVRO Quote, Financials, Valuation and Earnings

Electromed has a net margin of -50.32% compared to Nevro's net margin of 12.11%. Nevro's return on equity of -42% beat Electromed's return on equity of 15.91%.

Nevro has a consensus price target of $6.53, signalling upside risk potential of 12.64%. On the other hand Electromed has an analysts' consensus of $37.00 which suggests that it could grow by 50.28%. Given that Electromed has higher upside potential than Nevro, analysts believe Electromed is more attractive than Nevro.

Nevro has a beta of 0.943, which suggesting that the stock is 5.654% less volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Nevro quarterly revenues are $105.5M, which are larger than Electromed quarterly revenues of $16.3M. Nevro's net income of -$53.1M is lower than Electromed's net income of $2M. Notably, Nevro's price-to-earnings ratio is -- while Electromed's PE ratio is 32.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.53x versus 3.70x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Globus Medical has a net margin of -50.32% compared to Nevro's net margin of 4.03%. Nevro's return on equity of -42% beat Globus Medical's return on equity of 2.56%.

Nevro has a consensus price target of $6.53, signalling upside risk potential of 12.64%. On the other hand Globus Medical has an analysts' consensus of $98.69 which suggests that it could grow by 38.93%. Given that Globus Medical has higher upside potential than Nevro, analysts believe Globus Medical is more attractive than Nevro.

Nevro has a beta of 0.943, which suggesting that the stock is 5.654% less volatile than S&P 500. In comparison Globus Medical has a beta of 1.186, suggesting its more volatile than the S&P 500 by 18.608%.

Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

Nevro quarterly revenues are $105.5M, which are smaller than Globus Medical quarterly revenues of $657.3M. Nevro's net income of -$53.1M is lower than Globus Medical's net income of $26.5M. Notably, Nevro's price-to-earnings ratio is -- while Globus Medical's PE ratio is 94.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.53x versus 3.88x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -50.32% compared to Nevro's net margin of -2.16%. Nevro's return on equity of -42% beat Myomo's return on equity of -48.64%.

Nevro has a consensus price target of $6.53, signalling upside risk potential of 12.64%. On the other hand Myomo has an analysts' consensus of $8.85 which suggests that it could grow by 70.52%. Given that Myomo has higher upside potential than Nevro, analysts believe Myomo is more attractive than Nevro.

Nevro has a beta of 0.943, which suggesting that the stock is 5.654% less volatile than S&P 500. In comparison Myomo has a beta of 1.609, suggesting its more volatile than the S&P 500 by 60.902%.

Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Nevro quarterly revenues are $105.5M, which are larger than Myomo quarterly revenues of $12.1M. Nevro's net income of -$53.1M is lower than Myomo's net income of -$260.1K. Notably, Nevro's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.53x versus 6.02x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis has a net margin of -50.32% compared to Nevro's net margin of -118.53%. Nevro's return on equity of -42% beat Stereotaxis's return on equity of -139.2%.

Nevro has a consensus price target of $6.53, signalling upside risk potential of 12.64%. On the other hand Stereotaxis has an analysts' consensus of $4.50 which suggests that it could grow by 145.9%. Given that Stereotaxis has higher upside potential than Nevro, analysts believe Stereotaxis is more attractive than Nevro.

Nevro has a beta of 0.943, which suggesting that the stock is 5.654% less volatile than S&P 500. In comparison Stereotaxis has a beta of 1.546, suggesting its more volatile than the S&P 500 by 54.601%.

Nevro has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stereotaxis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nevro pays -- of its earnings as a dividend. Stereotaxis pays out -- of its earnings as a dividend.

Nevro quarterly revenues are $105.5M, which are larger than Stereotaxis quarterly revenues of $6.3M. Nevro's net income of -$53.1M is lower than Stereotaxis's net income of -$7.5M. Notably, Nevro's price-to-earnings ratio is -- while Stereotaxis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nevro is 0.53x versus 5.79x for Stereotaxis. Usually stocks with elevated PS ratios are considered overvalued.